image credit: Pixabay

FDA grants clearance for Endogena’s age-related macular degeneration treatment

October 25, 2023


The US Food and Drug Administration (FDA) has granted clearance for Endogena Therapeutics’ investigational new drug application to treat geographic atrophy (GA), an advanced form of age-related macular degeneration (AMD).

The FDA clearance will enable Endogena to progress with the clinical investigation of EA-2351.

Estimated to affect 9% of the population older than 45 years, AMD is an eye disease that can blur the central vision and is a leading cause of irreversible vision loss.

Read More on Pharma Times